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The Aristaless-related homeobox gene (ARX) is one of the major genes causing X-linked mental retardation. We have been interested in the
pathogenic mechanism of expanded polyalanine tract mutations in ARX. We showed that the c.304ins(GCG)7 mutation causing an increase from
16 to 23 alanines increased the propensity of ARX protein aggregation and a shift from nuclear to cytoplasmic localization. We proposed that
mislocalization of ARX via cytoplasmic aggregation and subsequent degradation leads to a partial loss of function, contributing to the
pathogenesis. We identified importin 13 (IPO13), a mediator of nuclear import for a variety of proteins, as a novel ARX interacting protein. We
predicted that the transport of ARX by IPO13 from the cytoplasm to the nucleus might be disrupted by expanded polyalanine tract mutations, but
our data showed that in both yeast and mammalian cells these mutant ARX proteins were still able to interact with IPO13. We established the
nuclear localization regions of the ARX homeodomain that were required for the interaction with IPO13 and correct localization of the full-length
ARX transcription factor to the nucleus.
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an estimated 1:600 males [1,2]. Although to date, Fragile X
syndrome is the most common form of XLMR, mutations in
numerous other genes leading to both syndromic and
nonsyndromic forms of XLMR are emerging [3]. One of
these genes is the Aristaless-related homeobox gene (ARX) [4].
Our laboratory originally characterized ARX and, together with
others, implicated it in XLMR phenotypes with intellectual
disability with or without additional features including epilepsy,
infantile spasms, dystonia, lissencephaly, autism, and dysarthia
[5–7]. As the prevalence of ARXmutations in XLMR continues
to emerge, it has been suggested that ARX may rival Fragile X
as a cause of mental retardation and epilepsy in males [8]. ARX⁎ Corresponding author. Fax: +61 8 8161 7342.
E-mail address: cheryl.shoubridge@adelaide.edu.au (C. Shoubridge).
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homeodomain proteins [9]. Conserved orthologs in mouse,
zebrafish [9], Xenopus [10], and Caenorhabditis elegans [11]
have been isolated. ARX is expressed predominantly in the
human fetal and adult brain and skeletal muscle [6,12,13]. A
role for Arx in regulating specific cell fate decisions is indicated
in a subset of GABAergic interneurons in the developing and
adult brain [14,15] and is crucial for mediating the correct
endocrine cell fate in the pancreas [16,17].
Expanded polyalanine mutations due to either a c.304ins
(GCG)7 (16 increasing to 23 alanines) or a c.428_451dup (12
increasing to 20 alanines) account for a considerable portion
(∼45%) of ARX mutations [4–6,12,18]. Expansion of the first
alanine tract has been identified in three families with X-linked
infantile spasms syndrome, also known as West syndrome (WS)
(MIM 308350) with infantile seizures, hypsarrhythmia, and MR
[6,18,19]. The c.428_451dup mutation expanding the second
tract has been found mainly in families with nonsyndromic MRc. All rights reserved.
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WS [6], sporadic MR [12,22], and families with Partington
syndrome (MIM 309510), whose symptoms include moderate
to severe MR, dystonic movement of the hands, and dysarthria
[6,21,23].
There is growing experimental support for expanded
polyalanine tract mutations contributing to disease via forma-
tion of mutant protein aggregates. Nine hereditary diseases are
caused by expansions of polyalanine tracts [24,25], eight of
which occur in transcription factors. Protein aggregation was
first noted in the expanded polyalanine tract mutations of the
PABPN1 gene [26]. This gene is implicated in oculopharyngeal
muscular dystrophy (MIM 164300) and is unique among the
other disease-causing expanded polyalanine-tract-containing
proteins as it is not a transcription factor but a polyadenylate-
binding protein [27,28]. More recently, studies examining
pathogenic mechanisms of expanded polyalanine tracts in
diseases involving FOXL2 (MIM 110100) [29], HOXD13
(MIM 186000), SOX3 (MIM 300123), RUNX2 (MIM
119600), and HOXA13 (MIM 140000) [30], and PHOX2B
(MIM 603851) [31] showed that the mutant proteins have the
propensity to form aggregates. Compared to the wild-type for
each protein, smaller expansions of alanine tracts lead to an
increased percentage of transfected cells with nuclear aggre-
gates [29–31]. Larger alanine repeats, with a threshold above
18–22 alanines, resulted in a high proportion of transfected cells
with mislocalization of the expressed protein to aggregates
within the cytoplasm [29–31].
We have been particularly interested in the pathogenic
mechanism of the expanded polyalanine tract mutations due to
either a c.304ins(GCG)7 or a c.428_451dup in ARX. The extent
of aggregate formation of expanded polyalanine tract mutations
of ARX and their involvement in pathogenesis remains unclear.
Initial reports from an in vitro study indicated that there was no
aggregate formation with overexpression of c.304ins(GCG)7
expanded polyalanine tract mutant protein [14]. In contrast, a
more recent study modeling the human c.304ins(GCG)7
mutation in mouse ortholog of ARX demonstrated accumula-
tion and formation of nuclear aggregates in approximately 30%
of cells transfected with the mouse mutant construct [32].
Support for nuclear aggregation of the c.304ins(GCG)7
mutation was provided in a recent review of ARX in cortical
development [33]. However, the more frequent 24-bp duplica-
tion mutation was not tested. Despite these data, we would
expect cytoplasmic aggregates with the longer 23-alanine tract
arising from the human c.304ins(GCG)7 mutation in light of the
studies in other disease-causing expanded polyalanine tracts.
The aim of this current study was to characterize aggregate
formation using the full-length human expanded alanine tract
mutations of ARX. Data from our study have shown that an
increase from 16 to 23 alanines in the c.304ins(GCG)7 mutation
was associated with an increased propensity of ARX protein
aggregation and a shift from nuclear to cytoplasmic localization.
However, there was no significant increase in aggregate
formation either in the nucleus or in the cytoplasm with the
more frequent c.428_451dup mutation, indicating that aggre-
gate formation is not a common pathogenic mechanism. Wewere interested to examine the effect of the polyalanine tract
mutations on the binding of ARX to importin 13 (IPO13) and
subsequent transport to the nucleus. We identified IPO13, a
member of the importin β superfamily that mediates nuclear
import of a variety of proteins [34,35], as a novel interacting
protein partner of ARX using yeast-2 hybrid screens and
coimmunoprecipitation studies. In yeast and mammalian cells
both mutant ARX proteins were able to interact with IPO13,
indicating that the cytoplasmic aggregation of the c.304ins
(GCG)7 mutant protein does not arise from a lack of binding to
IPO13. We propose that mislocalization of ARX via cytoplas-
mic aggregation and subsequent degradation leads to a partial
loss of function, contributing to the pathogenesis.
Results
c.304ins(GCG)7 ARX mutation forms cytoplasmic aggregates
in SH-SY5Y cells and PC12 cells
Before measuring aggregate formation with expanded
polyalanine tract mutations of ARX we established the rate
and location of aggregate formation of the wild-type ARX
protein in SH-SY5Y cells and PC12 cells. The results in both
cell types were almost identical and the data have been pooled.
Transient overexpression of green fluorescent protein (GFP)-
tagged wild-type ARX for 48 h resulted in aggregation in less
than 7% of all transfected PC12 and SH-SY5Y cells (Fig. 1).
The aggregates generally appeared as bright spots in the
nucleus. The rate of aggregate formation was consistently low at
24 and 72 h posttransfection (data not shown). Transfection of
the c.428_451dup mutant construct into either cell type resulted
in similar low levels of abnormal localization or aggregate
formation as seen in the wild-type ARX transfected cells (Fig. 1).
In contrast, overexpression of the c.304ins(GCG)7 ARX mutant
protein for 48 h resulted in abnormal localization or aggregate
formation in 40% of cells (Fig. 1), an approx sixfold increase
compared to wild-type ARX.
Subcellular localization of ARX expression (48 h post-
transfection) in SH-SY5Y and PC12 cells was categorized as
either (i) normal diffuse nuclear staining with little or no signal
in the nucleolus or surrounding cytoplasm or (ii) cells with
bright spot(s) in the nucleus (nuclear inclusions) or (iii) diffuse
signal with aggregates across the nucleus and cytoplasm
(cytoplasmic aggregates) (Figs. 2B–2D). Aggregates of the
normal and c.428_451dup mutant protein were predominantly
nuclear inclusions (Fig. 2A). In contrast, the c.304ins(GCG)7
ARX mutant protein formed aggregates with a predominant
perinuclear or cytoplasmic localization. In 80% of cells with
aggregation due to the c.304ins(GCG)7 ARX construct, the
mutant protein localized to large aggregates in the cytoplasm,
often to one side of the nucleus in addition to low levels of
diffuse nuclear staining (Figs. 2A and 2D). This pattern of
abnormal localization was also noted at 72 h posttransfection
(data not shown). Both the ARX aggregates inside the nucleus
(Fig. 2Ea) and those in the cytoplasm (Fig. 2Eb) costained with
an antibody against the heat shock protein Hsp70, regardless of
the construct tested.
Fig. 1. Percentage of abnormal subcellular localization of ARX expanded alanine tract mutations. (A) Schematic of the human ARX protein. Human ARX domains
and regions are indicated above the schematic and their locations are indicated below. Known functional domains are highlighted, octapeptide (OP) as horizontally
hatched rectangle, nuclear localization sequences (NLS) as three black rectangles, polyalanine tracts (PA) as four white rectangles, acidic domain as vertically hatched
rectangle, homeodomain crosshatched, and Aristaless domain (OAR) hatched. The open reading frame is indicated in boldface. The expanded alanine tract mutations
are shown in respect to the wild-type. (B) Full-lengthGFP-taggedARXWt (open bars), full-length c.428_451dup (gray bar), and full-length c.304ins(GCG)7 (black bar)
constructs were transfected into SH-SY5Y or PC12 cells for 48 h. The percentage of transfected cells displaying abnormal localization as nuclear inclusions or as
cytoplasmic aggregateswas determined from between 800 and 4000 cells per construct from at least three separate transfection reactions in both cell types. An all-groups
comparison of the percentage of abnormal cell localization of ARX expression in transfected cells was achieved by ANOVA. * p<0.001 vs ARXWt and c.428_451dup.
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tag used in these studies, we also used Myc-tagged and
nontagged ARX normal and mutant constructs (data not
shown) in both SH-SY5Y and PC12 cells. Our analysis showed
that the rate and subcellular localization of aggregate formation
of Myc-tagged or nontagged ARX constructs were not different
from those of the GFP-tagged ARX constructs. Tagged and
nontagged ARX were detected using an anti-ARX antibody that
we have generated. The specificity of this antibody was
confirmed by colocalization with GFP-tagged ARX by immu-
noflorescence (IF) (Fig. 3A) and detection of the same size band
as a commercially available anti-Myc antibody in a Myc–ARX
sample by Western immunoblot (WB) (Fig. 3B).
Increased cell death in SH-SY5Y cells transfected with
c.304ins(GCG)7 ARX
To ascertain whether the formation of aggregates correlated
with programmed cell death, the rate of apoptosis was measured
in SH-SY5Y cells transfected with ARX normal, c.428_451dup,
and c.304ins(GCG)7 ARX by terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) assay.
In nontransfected cells and lipofectamine-only-transfected cells,
the rate of TUNEL remained low at both 24 and 48 h
posttransfection (data not shown). In ARX transfection experi-
ments, only cells positive for ARX expression were then scored
for TUNEL signal. The levels of ARX transfected cells positive
for TUNEL were low at 24 h posttransfection with increasing
levels for all constructs at 48 h posttransfection (Fig. 4). At both
times tested the rate of cell death in cells transfected with
c.304ins(GCG)7 ARXwas markedly higher than that in either of
the other two constructs, correlating with increased aggregation
of the mutant protein in the cytoplasm.
Interaction of ARX and IPO13
To identify proteins that interact with ARX we performed
GAL4-based yeast-2 hybrid screening. In this paper we report
only on our findings of an interacting protein against the
homeodmain of ARX. Bait proteins were produced by fusing
the human ARX homeodomain (amino acids (aa) 303–431) to the
GAL4 DNA binding domain (GAL4-DBD). The bait protein did
Fig. 2. Aggregate formation of expanded alanine tract mutations in ARX. (A) Percentage of transfected SH-SY5Y and PC12 cells displaying nuclear inclusions or
cytoplasmic aggregates of GFP-tagged wild-type ARX (open bars), c.428_451dup (gray bars), and c.304ins(GCG)7 (black bars) protein 48 h after transfection. All-
groups comparison of the percentage of abnormal cell localization of ARX expression as either nuclear inclusions or cytoplasmic aggregates in transfected cells was
achieved by ANOVA. * p<0.001 vs ARX Wt and c.428_451dup transfected cells with cytoplasmic aggregate localization and to all ARX construct transfected cells
with nuclear inclusions. Subcellular localization of (B) wild-type ARX, (C) c.428_451dup, and (D) c.304ins(GCG)7 show normal nonhomogenous staining in the
nucleus (top) and abnormal localization as nuclear inclusions (middle) for all constructs and aggregates within the cytoplasm (bottom) for both polyalanine mutant
constructs. Cell nuclei were stained with DAPI (left) and GFP-tagged ARX (center) and the two images were merged (right). (E) Costaining of nuclear inclusions (a)
and cytoplasmic aggregates (b) of mutant ARX with an anti Hsp70 antibody.
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Fig. 3. Anti-ARX antibody detects tagged ARX proteins. The monoclonal anti-
ARX antibody (ARX-2-1A3_B5) detects GFP-tagged wild-type ARX protein in
transfected SH-SY5Y cells. (A) The green GFP tag is visualized using a
fluoroscein isothiocyanate filter. The antibody against ARX is detected using a
CY3-conjugated secondary antibody and visualized by a tetramethylrhodamine
isothiocyanate filter. The signal detected via the ARX2-1A3_B5 antibody
overlaps the GFP tag expressed with the ARX protein. (B) Cell lysates of Myc–
ARX transfected cells were subjected to SDS–PAGE and immunoblotted with
antibodies against ARX or Myc tag. There were no bands in the nontransfected
293T cell lysate (lane 1) but there was a band of ∼62 kDa (ARX 58 kDa+ Myc
4 kDa) in lysate from 293Tcells transfected with Myc-ARX (lane 2) using either
our ARX-2 1A3_B5 antibody or the commercially available anti-Myc antibody.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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transformation of MaV203 yeast but did autoactivate the lacZ
reporter gene (data not shown). Upon screening a human fetal
brain cDNA library with the bait protein, 1 of 33 double
transformants activated both the HIS3 and the URA3 reporter
genes (data not shown). Analysis of the single positive clone
transformed with the homeodomain identified the cDNA insert
from the interacting plasmid as the last 747 aa of IPO13 (importin
13, NM_014652). This cDNAwas not present in the list (http://Fig. 4. Percentage of ARX transfected cells positive for apoptosis was measured by T
bars), c.428_451dup (gray bars), and c.304ins(GCG)7 (black bars) constructs. Only c
posttransfection. Over 250 ARX transfected cells were counted per construct for eac
the percentage of TUNEL-positive ARX transfected cells was achieved by ANOVAwww.fccc.edu/research/labs/gelemis/InteractionTrapInWork.
html) of known false positives. The interaction between the ARX
homeodomain and the isolated IPO13 protein was confirmed by
yeast-based recombinational cloning.
The interaction between the IPO13 and the entire ARX protein
was initially confirmed in yeast and then in mammalian cells. In
yeast, the HIS3, URA3, and LacZ reporter genes were not auto-
activated with ARX normal protein fused to GAL4-DBD alone
but were activated when both full-length GAL4-DBD-ARX
normal protein and GAL4-AD-IPO13 were transformed into
MaV203 yeast (data not shown). In mammalian cell studies, to
increase the cellular amount of IPO13 for coimmunoprecipitation,
the last 747 aa of IPO13 tagged to V5 was transiently transfected
into HEK 293T cells along with Myc-tagged normal ARX. This
truncated version of IPO13 lacks the RanGTP binding site and
maximizes the likelihood of detecting the otherwise transient
interaction between ARX and IPO13. A monoclonal anti-V5
antibody was used to immunoprecipitate V5-IPO13 from whole-
cell extracts. Coimmunoprecipitated Myc-tagged ARX was
detected by an anti-Myc antibody conjugated to horseradish
peroxidase (HRP) (Fig. 5A), indicating that IPO13 and full-length
ARX associate in HEK 293Tcells. The interaction betweenMyc-
tagged ARX and IPO13 was confirmed in cotransfected cells by
immunoflorescence. Endogenous IPO13 (Fig. 5Ba) and V5-
IPO13 (Fig. 5Bb) were detected as diffuse signals across the cell
cytoplasm and nucleus in untransfected cells. Endogenous IPO13
signal was not affected by transfection of ARX (Fig. 5Ca),
indicating the transient interaction of these proteins. However, the
RanGTP-binding-site-deficient V5-IPO13 colocalized with
cotransfectedARX (Fig. 5Cb). To ascertainwhether the expanded
polyalanine mutations in ARX disrupt the normal interaction with
IPO13, these procedures were repeated using c.304ins(GCG)7
ARX or c.428_451dup ARX in place of normal ARX. Coimmu-
noprecipitation (Fig. 5A) and immunoflorescence confirmed that
both expanded polyalanine tract mutant proteins interact with
IPO13 whether ARX was located diffusely to the nucleus or as
aggregates in the nucleus (Fig. 5Cc) or the cytoplasm (Fig. 5Cd).UNEL. SH-SY5Y cells were transfected with GFP-tagged wild-type ARX (open
ells positive for ARX transfection were scored for TUNEL signal at 24 and 48 h
h time point, from at least three separate experiments. All-groups comparison of
. * p<0.001 vs ARX Wt and c.428_451dup within each time point.
Fig. 5. ARX interacts with IPO13 in mammalian cells. (A) HEK 293 T cells transfected with Myc-ARX (wt) or c.304ins(GCG)7 (in) or c.428_451dup (du) and V5-
IPO13 were lysed and proteins were immunoprecipitated (IP) with rabbit anti-V5 antibody. Samples were loaded on 4–12% SDS–PAGE gels and analyzed for the
presence of Myc-ARX bound to V5-IPO13 by immunoblotting with mouse anti-Myc HRP-conjugated antibody (top). The presence of Myc-ARX and V5-IPO13
present in the immunoprecipitate are shown in the middle and bottom, respectively. Cells transfected with Myc-ARX alone or V5-IPO13 alone were used as negative
controls. (B) Endogenous IPO13 (a) and transfected V5-IPO13 (b) staining using a polyclonal anti-IPO13 antibody was seen as bright signal in the cytoplasm and
across the nucleus. (C) In cells transfected with ARX alone, endogenous IPO13 was strongest in the cytoplasm and did not colocalize with the ARX signal in the
nucleus (a), reflecting the transient interaction of these proteins. When Myc-ARX or c.304ins(GCG)7 or c.428_451dup ARX and RanGTPase-binding-site-deficient
V5-IPO13 plasmids were cotransfected into cells, the IPO13 localization reflected ARX localization in all cells that expressed both proteins, regardless of whether
ARX was localized to the nucleus (b) or in aggregates in either the nucleus (c) or the cytoplasm (d).
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(NLS) in the homeodomain of ARX
There are four naturally occurring mutations (R332P,
R332H, R332C, and T333N) in the homeodomain NLS2
region. The mechanism of pathogenesis of these mutations is
not known. The four point mutations were introduced into an
otherwise normal homeodomain construct (Fig. 6A) to establish
whether these point mutations disrupt the interaction of ARX to
IPO13 in yeast. Constructs containing a point mutation in NLS2
activated theHIS3 (Fig. 6B) andURA3 reporter gene expression
when GAL4AD-IPO13 was present (data not shown), suggest-
ing that none of these point mutations by themselves were
able to significantly affect the binding of IPO13 to ARX
homeodomain in yeast. However, deletion of NLS2 (ARX-
HDΔNLS2) resulted in patchy activation of the reporter genes
in only a few colonies (8/25 colonies in repeated experiments)
and deletion of NLS3 (ARX-HDΔNLS3) completely (0/25
colonies) abolished reporter gene activation (Fig. 6C). To
ensure that this lack of binding between ARX-HDΔNLS3 andIPO13 was due to deletion of NLS3 residues, we mutated the
individual residues in NLS3 (shown in boldface in Fig. 6A) by
site-directed mutagenesis. Mutation of NLS3 residues also
resulted in no interaction between the mutant ARX home-
odomain and the IPO13 in yeast (Fig. 6C), suggesting that these
residues in NLS3 are vital for this interaction.
Interaction of IPO13 with the C-terminal nuclear localization
sequences in the homeodomain of ARX is required for correct
nuclear localization
We wanted to confirm the function of IPO13 binding to NLS
regions in the ARX homeodomain in the subsequent localization
of this transcription factor to the nucleus in mammalian cells.
Key basic residues in NLS regions of the homeodomain in full-
length Myc∼tagged ARX constructs were mutated by site-
directed mutagenesis (Fig. 7A) and then transiently transfected
into 293T cells with and without cotransfection of V5-IPO13.
The putative NLS1 region was not targeted for mutation analysis
as subcellular localization studies using partial ARX constructs
Fig. 6. Yeast screening of IPO13 interaction with normal and mutant ARX homeodomain constructs. (A) Schematic of the partial ARX protein, with the amino acid
location indicated above, containing the homeodomain is depicted with the NLS2 and NLS3 regions as black boxes. The sequences in boldface above the black boxes
for NLS2 and NLS3 depict basic residues that are part of NLS-like motifs. Missense mutations identified in NLS2 are shown above the sequence. (B) ARX
homeodomain constructs are indicated on the left, with the yeast-2 hybrid screening results on the right. All MaV203 yeast colonies transformed with both the GAL4-
DBD-ARX construct and the GAL4-AD-IPO13 are able to grow on the -L-W master plate. Colony growth on the HIS3 (30 mM 3AT) reporter plate is achieved only if
the two constructs interact to allow reporter gene expression. Five Yeast Control MaV103 Strains (Control A–E) included with the ProQuest Yeast-2 Hybrid System
contain plasmids expressing fusion proteins which have a spectrum of interacting strengths from no interaction in Strain A to very strong interaction in Strain E. (C)
ARX homeodomain constructs with either the NLS2 or the NLS3 region deleted or individual residues in NLS3 mutated (left). Two rows of 10 MaV203 yeast colonies
per construct transformed with both the GAL4-DBD-ARX and the GAL4-AD-IPO13 constructs all grow on the -L-W master plate (middle) with protein interaction
determined by growth on the HIS3 (20 mM 3AT) reporter plate (right).
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not crucial for ARX nuclear localization. ARX-Poly(A) partial
construct (aa 61–174) contained the NLS1 region (aa 82–89)
and the homeodomain construct (aa 303–431) contained both
the NLS2 and the NLS3 regions (Fig. 7B). These partial
constructs were transiently transfected into 293T cells and
expressed protein was visualized using an anti-myc antibody.
The homeodomain clearly locates to the nucleus (Fig. 7Bb)
while the construct containing the NLS1 region is localized
diffusely in the cytoplasm (Fig. 7Ba).
Disruption of residues in the NLS2 region or the NLS3
region (Fig. 7Cc) both resulted in abnormal subcellularlocalization of the full-length ARX protein in transfected
cells. Mutations in NLS2 resulted in large aggregates either in or
over the nucleus (Fig. 7Cb) in 32% of transfected cells (Fig.
7D), suggesting that NLS3 can function in ∼70% of cells to
correctly localize ARX to the nucleus. In contrast, when
residues in NLS3 are mutated, over 60% of all transfected cells
(Fig. 7D) display the mutant protein localized to large
aggregates in the cytoplasm (Fig. 7Cc). These data clearly
suggest that a functioning NLS2 alone is not enough to correctly
localize the ARX transcription factor to the nucleus. Cotrans-
fection of V5-IPO13 with the Myc-tagged ARX wt (Fig. 7Eb)
and ARX-NLS2 mutant (Fig. 7Ec) constructs shows that the
Fig. 7. Changes in nuclear localization of full-length ARX in 293Tcells when the NLS regions are disrupted. (A) Schematic of the full-length ARX protein (domains as
illustrated in Fig. 1A) is depicted with the NLS regions as three black boxes. The sequences in boldface above the black boxes for NLS2 and NLS3 depict basic
residues that are part of NLS-like motifs, with the mutations introduced by site-directed mutagenesis listed above individual residues. (B) Partial ARX constructs
containing the NLS1 region (ARX-Poly(A)) and the ARX homeodomain (ARX-HD) region are depicted, with the amino acid location indicated above. Partial
constructs transfected into 293Tcells and expression detected via an anti-Myc antibody and a TRITC-labeled secondary antibody (left) with the merged image showing
DAPI staining of cell nuclei (right). The NLS1-containing construct did not localize to the nucleus of transfected 293T cells although partial constructs with the NLS2
and NLS3 regions did localize exclusively in the nucleus. (C) The subcellular localization of Myc-ARXwild-type (a) changes when ARX constructs with mutations in
NLS2 (b) or NLS3 (c) are transiently transfected into 293T cells, detected using our anti-ARX-21A3_B5 antibody and a FITC-labeled secondary antibody (left) and
merged with image of DAPI-stained cell nuclei (right). (D) Percentage of transfected cells with abnormal localization increased following expression of ARX-NLS2
mutant (gray bar), with even higher levels with ARX-NLS3 mutant (black bar) as compared to ARX Wt (open bar). At least 2000 transfected cells were counted for
each construct, from three separate experiments. (E) V5-IPO13 transfected into HEK 293Tcells localizes diffusely across the cell cytoplasm. All-groups comparison of
the percentage of abnormal cell localization of ARX expression in transfected cells was achieved by ANOVA. * p<0.001 vs ARX Wt and ARX-NLS2 mutant, with
ϒ P<0.001 vs ARXWt and ARX-NLS3 mutant. (E) (a) Cotransfection of V5-IPO13 with the Myc-tagged ARXWt (b) and ARX-NLS2 mutant (c) constructs shows
that the IPO13 changes its localization pattern to mirror the nuclear localization of ARX, indicating that these proteins are interacting. Cotransfection of V5-IPO13 with
ARX-NLS3 mutant constructs results in cells with large cytoplasmic aggregates that are positive for both ARX and IPO13 (d) but are not localized to the nucleus.
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staining (Fig. 7Ea) to mirror the nuclear localization of
ARX. This indicates that, although the NLS2 region of the
homeodomain is mutated, the NLS3 region is adequate to bind
IPO13 and in the majority of cells can enable correct transport
of ARX to the nucleus. The IPO13 signal in cells cotransfected
with the ARX-NLS3 mutation construct show an overlapping
subcellular signal with ARX-NLS3 mutant protein (Fig. 7Ed),
indicating that NLS2 alone can at least bind IPO13. However,
the subcellular localization of these proteins was in large
aggregates outside of the nucleus in the cytoplasm (Fig. 7Ed).
Hence, the interaction of IPO13 with the NLS3 region of the
ARX homeodomain is vital for the correct transport of this
homeobox transcription factor protein into the nucleus.
Discussion
In this study we have shown that overexpression of the
c.304ins(GCG)7 mutant caused a significant increase in protein
aggregation compared to either the normal wild-type ARX
sequence or the c.428_451dup mutant. This increased propen-
sity of the c.304ins(GCG)7 mutant alanine tract to aggregate
was in agreement with the data previously reported [32].
However, this previous report indicated that aggregates of
mouse Arx sequence, with insertion of additional alanines to
mimic the human situation, were observed as nuclear
inclusions. In contrast, we have shown that the location of
aggregates shifted from predominantly nuclear inclusions with
normal and duplication mutation protein expression to a
predominantly perinuclear or cytoplasmic location of aggrega-
tion with the 23 alanine tract mutant protein. Experimental data
presented for FOXL2, HOXA13, HOXD13, PHOX2B,
RUNX2, and SOX3 also show that mutations leading to longer
polyalanine tracts result in cytoplasmic aggregation of the
mutant protein [29–31]. These experimental data are well
aligned with the theory of expanded alanine protein aggregation
in an alanine-dose-dependant manner, with cellular environ-
ment influencing the threshold or propensity to aggregate.
ARX belongs to a growing number of disease-causing genes
with mutations that lead to expanded polyalanine tracts. These
expanded alanine tracts are stably transmitted across multiple
generations with many giving rise to congenital defects [25,36].
The lengths of normal alanine tracts are similar in all
transcription factors (12–20 alanines) and so is the amount of
increased length of these tracts that cause disease (18–29
alanines). The pathogenic mechanism of expanded polyalanine
tract mutations is not clear. In the case of ARX, a gain of
function hypothesis is unlikely as these polyalanine expansion
mutations are inherited in an X-linked recessive fashion with
carrier females largely unaffected. The clinical similarity of
polyalanine expansion mutations and some point mutations
[6,13] indicates a partial loss of function of this homeobox
transcription factor as a likely pathogenic mechanism. This
could occur by a number of different mechanisms. Aggregation
of the mutant protein could result in a loss of transcriptional
activity or it could disrupt normal cellular processes due to the
aggregates themselves. Recent work in our laboratory does notsupport a loss of transcriptional activity due to expanded
polyalanine tract mutations in ARX [37]. Arx has been
established as a transcriptional repressor [17] influencing cell
fate decisions [14,16,17]. Studies in our laboratory have
confirmed, in cell-based assays, that ARX acts as a strong
transcriptional repressor and have established that the majority
of the repression resides in the fourth, highly conserved
polyalanine tract [37]. The repression activity of ARX was
unaffected by the c.428_451dup mutation and was increased by
the c.304ins(GCG)7 ARX mutant construct. Hence, we can
speculate that one cause of ARX dysfunction due to expanded
polyalanine tracts may arise in part from increased repression
activity of mutant ARX homeobox protein. Disturbance to the
normal transcriptional repression during early brain develop-
ment could lead to inappropriate gene expression and
subsequent disturbance of normal cell development and tissue
patterning. The severe “loss of function” phenotypes of ARX do
indeed result in a disturbed patterning of the cortical tissue in the
brain, thought to arise from incorrect migration of neurons
during early brain development [13]. Hence, changes in the
transcriptional activity of ARX due to these expanded
polyalanine tract mutations may have subtle effects on neuronal
organization and may contribute to pathogenesis of the affected
individuals.
In our study we did not observe any significant increase in
the propensity of the c.428_451dup mutant protein to aggregate
or change in localization compared to the wild-type protein.
These data indicate that very likely soluble protein with altered
function is the key molecular pathogenesis of ARX polyalanine
tract expansions. In contrast, as the aggregates of the c.304ins
(GCG)7 mutant protein mislocalized to the cytoplasm, we can
predict that the lack of the transcription factor being located to
the nucleus may lead to partial loss of function, even though the
mutation itself does not abolish the transcriptional activity of
ARX [37]. Despite experimental evidence of longer expanded
polyalanine tract mutations forming aggregates, the clinical
relevance of these aggregates remains to be established for
many of the genes implicated. For example, PABPN1, a poly(A)
binding protein, is the only disease-causing gene due to alanine
expansion mutations that is not a transcription factor and in
which intranuclear inclusions are reported as a pathological
hallmark of OPMD (MIM 164300) [28,38,39]. However, the
filaments of PABPN1 have also been observed in neurons as
dynamic structures whose appearance depends upon changes to
cellular activity [40]. Hence, the contribution of aggregates of
expanded alanine mutant PABPN1 protein to the pathogenesis
of OPMD remains speculative.
Another possible pathogenic mechanism of these expanded
alanine tract mutations would be a disruption of the binding of
the mutant protein to its normal DNA targets or interacting
proteins. In the case of ZIC2, the phenotype arising from loss of
function mutations is not noticeably different from that arising
from the naturally occurring mutation increasing the 15 alanine
tract to 25 alanines [41]. Functional studies indicate that the
expanded alanine mutant protein of ZIC2 influences the
strength of DNA binding, resulting in a near complete loss of
the normal levels of transcriptional activity [41]. Similarly,
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activation of luciferase reporter gene downstream of the
proximal promoter of Hesx1, a purported binding site for
SOX proteins [42]. This reduced activity is thought to be
primarily due to an inability of the mutant protein to bind to the
DNA binding site correctly. A complete “loss of function” of
ARX due to expanded polyalanine mutations appears unlikely
given frameshift mutations that lead to premature termination of
ARX protein, resulting in a very severe phenotype of X-linked
lissencephaly with abnormal genitalia (XLAG) (MIM 300215)
[13], and this phenotype has never been reported for either
expanded alanine tract mutation of ARX. Nor does it appear that
these mutations abolish the binding of ARX to the novel
interacting protein partner, IPO13. We have established an
interaction between ARX and transport protein IPO13 by yeast-
2 hybrid studies and coimmunoprecipitation. Although we
predicted that the formation of cytoplasmic aggregates with the
c.304ins(GCG)7 mutant protein may arise from a lack of
adequate delivery of the mutant protein to the nucleus, we
demonstrated that IPO13 continues to bind to ARX despite
expansion of the polyalanine tracts. However, we cannot
exclude the possibilities that the binding of these expanded
polyalanine tract mutant ARX proteins to IPO13 may be less
efficient than that of the normal ARX protein and may lead to
compromised nuclear import, contributing in part to the
molecular pathogenesis of these disorders.
IPO13 has been shown to mediate the nuclear import of the
proteins PAX6, PAX3, and CRX by binding to NLS sequences
associated with Paired-type homeodomains [35]. These same
highly conserved NLS sequences have also been shown to be
important for the nuclear localization of the Paired-class
homeodomain proteins CART1, VSX-1, and OTX1 [43–45].
Four naturally occurring point mutations within these highly
conserved residues of NLS2 in ARX have been shown to cause
X-linked lissencephaly with ambiguous genitalia (XLAG)
(R332P, R332H, and R332C) [7,13,46] and Proud syndrome
(T333N) [13]. We therefore examined the interaction between
IPO13 and ARX homeodomain with mutations in NLS2 by
yeast-2 hybrid analysis. Interestingly, we found that the four
point mutations had no effects on the interaction between ARX
homeodomain and IPO13. However, since the binding of IPO13
to PAX6 was found to be stronger with the NLS at the C-
terminal end of the homeodomain [35], we speculated that the
interaction between IPO13 and NLS3 of ARX was sufficiently
strong to activate yeast reporter gene expression. Our study
confirmed that the interaction of IPO13 was abolished when the
NLS3 region of the ARX homeodomain was removed or
mutated. Indeed, disruption of key residues within the NLS3
region of the full-length protein resulted in the protein
inappropriately localizing outside the nucleus in the majority
of transfected cells. When key residues of the NLS2 region were
disrupted, however, a smaller proportion of cells with abnormal
ARX localization was observed. Therefore, although point
mutations in NLS2 of ARX may still enable the protein to
interact with IPO13 through its binding to the intact NLS3,
these mutations may have subtle affects on the ability of IPO13
to import ARX into the nucleus efficiently or to correctlydistribute the protein once inside the nucleus. Subtle differences
in the amounts of ARX imported to the correct location within
the nucleus during development may affect important transcrip-
tional regulatory events during GABAergic interneuron pro-
liferation, differentiation, and migration and may contribute to
XLAG or Proud syndrome. Alternatively, these point mutations
may make no significant difference to the import of ARX into
the nucleus but may affect the binding of ARX to DNA or other
transcriptional factors or may influence other posttranslational
modifications of this homeobox transcription factor.
Materials and methods
Construction of ARX-containing vectors
Gateway cloning and expression vectors (Invitrogen) were used unless
otherwise stated. All clones were sequenced to exclude introduced errors and the
concentration was determined spectrophotometrically.
Full-length human ARX construct (ARX Wt) was produced by a series of
PCRs from genomic DNA purified from blood and the PCR products were
ligated together via compatible restriction sites. The construct was cloned into a
range of expression vectors, including phrGFP-N1 (Stratagene) and the Gateway
vectors including pcDNA3.2/V5-DEST and Gateway-compatible pCMV-Myc
(BD-Biosciences) expression vectors for cell transfections and pDEST32 vector
for yeast-2 hybrid screening. The expanded polyalanine mutations were
amplified from genomic DNA of affected individuals and inserted into full-
length constructs (c.304ins(GCG)7 ARX and c.428_451dup ARX). The residues
in the homeodomain NLS regions of the full-length pCMV-Myc-ARX
constructs predicted to be important in binding to IPO13 (underlined) were
mutated by site directed mutagenesis using the QuikChange site-directed
mutagenesis kit (Stratagene) following manufacturer’s instructions. ARX-NLS2
normal Lys-Arg-Lys-Gln-Arg-Arg-Tyr-Arg → mutant Lys-Ser-Ile-Gln-Gly-
Gly-Tyr-Gly, ARX-NLS3 normal Arg-Arg-Ala-Lys-Trp-Arg-Lys-Arg →
mutant Gly-Gly-Ala-Lys-Trp-Ser-Lys-Arg. IPO13 (aa 217–747) were cloned
into pcDNA3.1/nV5-DEST for mammalian cell culture studies.
For yeast-2 hybrid screening, standard PCR and subcloning techniques were
used to generate a partial ARX construct which contains the homeodomain
(ARX-HD; aa 303–431) from human fetal brain cDNA (Clontech) fused in
frame with the GAL4 DNA binding domain in the Gateway pDEST32
expression vector. IPO13 (aa 217–747) was also cloned into the vector
pDEST22 where it would then be fused in frame with the GAL4 activation
domain. Missense mutations introduced into the ARX-HD construct included
c.994C>T leading to R332C (ARX-HD-R332C), c.995G>C leading to R332P
(ARX-HD-R332P), c.995G>A leading to R332H (ARX-HD-R332H), and
c.998C>A leading to T333N (ARX-HD-T333N). NLS regions within the ARX
homeodomain were deleted to examine the effects of each on binding to IPO13
in yeast. ARX-HDΔNLS2 contains aa 337–431, ARX-HDΔNLS3 contains aa
303–376, and point mutations in NLS2 without the NLS3 sequence included
ARX-HD-R332CΔNLS3 and ARX-HD-T333NΔNLS3.
Cell culture
Rat pheochromocytoma cells (PC12) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% (v/v) fetal calf
serum (FCS) and 10% (v/v) horse sera. Human neuroblastoma SH-SY5Y cells
were cultured in a 1:1 mixture of DMEM and Ham’s F12 medium with 10%
FCS. HEK 293Twere maintained in DMEM supplemented with 10% (v/v) FCS.
All cells were cultured in the presence of 100 U/ml sodium penicillin and
100 μg/ml of streptomycin sulfate in 5% CO2 at 37 °C.
Antibody production
We have produced a monoclonal antibody to a small peptide region of the
mature ARX protein (KISQAPQVSISRSKSYREN; (aa 161–17) with 100%
amino acid homology across human mouse and zebrafish species. A custom-
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to the peptide via maleimidocapryl-N-hydoxysuccinimide. BALBc mice were
immunized with 50 μg protein per mouse in 200-μl bolus administered by
subcutaneous injection. A priming injection of peptide in Freud’s complete
adjuvant was followed with a second and third boost of peptide in Freud’s
incomplete adjuvant and a fourth boost of peptide in phosphate-buffered saline
(PBS), with each treatment at fortnightly intervals. The mice were culled 3 days
after the final boost to harvest the spleen. The dissociated spleen cells were fused
to myeloma cells to allow the formation of antibody-producing hybridomas
under the selection of HAT media. Conditioned media from the resulting
hybridomas were screened for reactivity against the peptide used to inoculate the
mice. Clones that gave a positive enzyme-linked immunosorbent assay result
against the specific peptide and little or no cross-reactivity to either diptheria
toxoid or bovine serum albumen (BSA) were tested against the mature protein
by immunoflorescence and Western immunoblot. A successful clone, ARX-2
1A3, was haplotyped as an IgG antibody and, after subcloning the B5 daughter
clone, was selected for use.
Antibodies
The following antibodies were used for immunoflorescence and/or Western
immunoblot analyses: mouse anti-ARX (2 μg/ml final) (IF andWB), rabbit anti-
HSP70 (1:200) (IF) (Chemicon Int.); mouse anti-Myc HRP-conjugated antibody
(1:5000) (WB) (Invitrogen); rabbit anti-V5 antibody (1:5000) (WB) (Bethyl
Laboratories); and rabbit anti-IPO13 (1:1000) (IF) kindly provided by Professor
Dirk Görlich, (ZMBH, Heidelberg, Germany). The secondary antibodies were
goat anti-mouse antibody conjugated to CY3 (IF) and goat anti-rabbit antibody
conjugated to FITC or CY3 secondary (1:1000) (IF) (Jackson Laboratories) and
peroxidase goat anti-mouse IgG (1:1000) (WB) (DakoCytomation).
Transfection studies
Cells were plated onto sterile glass coverslips at 1×106 cells per well in a
six-well plate for HEK 293T cells and at 2×105 cells per well for SH-SY5Yand
PC12 cells. Routinely, cells were transfected with 1–2 μg of plasmid DNA using
lipofectamine 2000 (Invitrogen) following manufacturers instructions. Cells
were fixed at 24 and 48 or 72 h after transfection with 3.7% formaldehyde–PBS
before mounting onto slides with Dapi-anti-fade mounting media visualized by
standard fluorescence microscopy (Olympus Australia) or stored at 4 °C until
probed with antibodies (see below).
Western immunoblotting
293T cells transfected with 1 μg Myc∼ARX constructs were harvested and
cell lysates were made for coimmunoprecipitation. Lysates were then run in
replicates (3 μl per lane), subjected to SDS–PAGE, transferred to nitrocellulose,
and analyzed by immunoblotting. Signal was detected via chemiluminesence.
Immunoflorescence and microscopy
Fixed cells were permeabilized in 0.2% (v/v) Triton PBS for 5 min.
Blocking of nonspecific binding of the secondary antibody was achieved
routinely by addition of 5% goat sera in 1% BSA in Tris-buffered saline and
0.5% Tween (TBS-T) before incubation of the primary and secondary
antibodies diluted in 1% BSA-TBS-T. Removal of excess block and antibody
was achieved with multiple washes of TBS-T. Nuclei were counterstained with
DAPI (Molecular Probes, Invitrogen). Over 1000 transfected cells were counted
for each construct from at least three different transfection reactions. The
formation of aggregates was assessed using standard florescence microscopy.
The percentage of transfected cells with aggregates was determined as the
number of cells containing aggregates divided by the total number of ARX-
positive cells.
Cell death assay
SH-SY5Y cells transfected for 24 and 48 h were fixed and stained with anti-
ARX antibody as described above, with the exception of 0.1% (v/v) Triton incitrate used as the permeabilization buffer. After the secondary antibody was
washed off the sections were rinsed twice with PBS and then incubated with TdT
enzyme and UTP-TMR red at 37 °C for 1 h (Roche). Transfected cells were
scored for presence of TUNEL staining. The rate of TUNEL staining in
nontransfected cells was determined by counting all TUNEL-positive cells in
one pass of the middle of each coverslip from top to bottom. There were no
differences in the rates of TUNEL staining in nontransfected cells at each time
point in the three ARX constructs (data not shown).
Yeast-2 hybrid screening and interaction testing
Plasmids encoding the ARX domains were fused to the GAL4 DNA binding
domain and the library proteins were fused to the GAL4 activation domain. The
MaV203 yeast strain was cotransformed with the ARX-HD construct and the
human fetal brain cDNA library (ProQuest, Invitrogen). Colonies were selected
on media lacking leucine, tryptophan, and histidine and positive clones were
analyzed for the three reporter genes HIS3, URA3, and lacZ which were
measured by β-galactosidase activity. Library inserts of positive clones that
activated more than one reporter gene were amplified by PCR and sequenced to
determine the identity of the library clone. Interaction between the ARX
homeodomain and the isolated clones was confirmed by yeast-based
recombinational cloning as described previously [47].
Coimmunoprecipitation
To verify the interactions between Myc-ARX and V5-IPO13, cotransfected
HEK 293T cells were lysed and immunoprecipitated with mouse anti-Myc
antibody (Santa Cruz Biotechnology) and then coupled to protein-A Sepharose.
Immunoprecipitated proteins were analyzed for the presence of Myc-ARX by
Western immunoblotting using mouse anti-Myc HRP-conjugated antibody and
V5-IPO13 was performed with rabbit anti-V5 antibody followed by goat anti-
rabbit HRP-conjugated secondary antibody. Cell lysates were prepared using
lysis buffer (120 mMNaCl, 50 mM Tris–HCl (pH 8.0), 0.5% Nonidet-P40 (NP-
40), 1X protease inhibitor cocktail (Sigma), 1 mM Na3VO4, 1 mM NaF, 1 mM
phenylmethylsulfonyl flouride), clarified by centrifugation (15 min, 13,000 g),
and precleared with protein-A Sepharose. Aliquots of extracts were immuno-
precipitated overnight at 4 °C. The lysates were then incubated with 40 μl of
protein-A Sepharose for 1 h at 4 °C before being washed four times with 0.4 ml
of wash buffer (500 mM NaCl, 20 mM Tris–HCl (pH 8.0), 1 mM EDTA, 0.5%
NP-40) and eluted in SDS loading buffer (62.5 mM Tris–HCl (pH 6.8), 2%
SDS, 10% glycerol, 5% β-mercaptoethanol, 0.001% bromophenol blue).
Lysates from transfected HEK 293T cells producing either Myc-ARX alone or
V5-IPO13 alone were used as controls.
Statistical analysis
All data are reported as mean±SE for the percentage of transfected cells with
abnormal subceullular localization or TUNEL. These data were determined
from a minimum of three separate transfection reactions, with the number of
transfected cells counted per construct indicated in each figure legend.
Differences in the percentage of transfected cells with abnormal subceullular
localization or TUNEL within each experiment were analyzed by one-way
ANOVA using least-significant difference post hoc test for all pairwise
comparisons when significance was reached. p<0.05 was considered
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